Maine Molecular Quality Controls, Inc. designs and markets molecular controls for use in inherited disease testing and infectious disease detection.
As experts in quality assurance of laboratory medicine, MMQCI produces high caliber controls uniquely suited to monitor all phases of molecular testing as required by best practice and regulations. MMQCI controls provide confidence in test results.
MMQCI continues to design and produce innovative, high-quality control products as needed for emerging nucleic acid technologies as they come into use by the molecular diagnostic community. Custom orders from in vitro diagnostic manufacturers are always welcome at MMQCI's cGMP facility.
The company was formed in January 2000 by the two principals, Joan Gordon MT (ASCP) and Clark Rundell, Ph.D. Both founders of MMQCI have a strong background in clinical laboratory testing, as well as extensive research and development skills in the molecular biology field. As long-term workers in a clinical laboratory at Maine's largest healthcare facility, they are thoroughly familiar with the importance of controls in assuring laboratory accuracy, as well as the Federal regulations governing their use. While implementing novel genetic testing assays in the newly established Maine Medical Center Molecular Pathology Laboratory, Dr. Rundell invented and patented a process to stabilize target DNA constructs for utilization as controls in molecular-based diagnostic assays. Ms. Gordon, President of MMQCI, developed protocols based on this patented process to manufacture an FDA-cleared quality control for an infectious disease test platform. Dr. Rundell and Ms. Gordon subsequently founded MMQCI to pursue further research and development of unique technologies to produce additional molecular control products. Funds from the National Institutes of Health and Maine Technology Institute have assisted the development of new technologies used in MMQCI products.
Provide high caliber quality controls to support the goal of achieving 100% accuracy of patient molecular test results.
Joan H. Gordon, MT (ASCP)
President
Ms. Gordon co-founded our company in 2000 and serves as President and Chief Executive Officer. Prior to founding Maine Molecular Quality Controls, Inc. Ms. Gordon was senior technologist at the Maine Medical Center and then Research Associate at the Maine Medical Center Research Institute. Ms. Gordon’s scientific expertise is in molecular genetic testing and molecular cloning technology. She developed the technical protocols for production and manufacturing the nucleic acid constructs in MMQCI’s products. She is co-inventor on two patents. Ms. Gordon is treasurer of the AACC, Industry Division and a member of the Annual Meeting Organizing Committee for 2006. She received her B.S. in Medical Technology (Suma Cum Laude) from the University of Vermont. She pursued graduate studies in Applied Immunology and Molecular Biology at the University of Southern Maine.
Clark A. Rundell, Ph.D. DABCC
Vice President of Research
Dr. Rundell co-founded our company in 2000 and serves as Vice President of Research. Prior to founding Maine Molecular Quality Controls, Inc. Dr. Rundell was Director of Chemistry at the Maine Medical Center and then Director of Chemistry and Molecular Diagnostics at NorDx Laboratories. Dr. Rundell’s scientific expertise is in molecular genetic testing and chemistry. He developed technologies for stabilizing nucleic acid constructs in MMQCI’s control products. Dr. Rundell is co-inventor on several patents. He was a Postdoctoral Fellow at Purdue University and Postdoctoral Fellow in Clinical Chemistry at the University of Maryland Hospital. Dr. Rundell received his B.S. from St. Cloud State University and his Ph.D. from the University of North Dakota.